Challenges and Strategies to Facilitate Formulation Development of Pediatric Drug Products

Session 5: Excipient Safety

Organizing Committee:
Aylward, Baer, Buckley, Carleer, Fegley, Nunn, Salunke, Turner, Thompson
Session 5: Pre-Read Material

- EMA Guideline on Excipient Labeling (Review example of propylene glycol, esp Q&A)
- EMA Reflection paper on extrapolation of efficacy and safety in paediatric medicine development. 01Apr2016 DRAFT
- IPEC Position paper on EU Risk Assessment Guidelines for Excipients (2015/C95/02)
- Sources of information supporting excipient use
  - FDA inactive ingredients and IPEC Comments
  - STEP database (Safety and Toxicity of Excipients for Pediatrics)
    - http://pharmacyapp-a.ucl.ac.uk:8080/eupfi/appDirectLink.do?appFlag=login;
Session 5: Case Scenarios & Questions to Inform Development of a Risk Assessment Framework

Two Breakout discussion groups:

1. New/Novel excipients
   - “Inactive” vs biologically active agents (e.g. SNAC)
   - European vs. US approaches

2. Established/Standard excipients with incomplete information (e.g. new use: dose, duration, route, severity of diseases, age group, etc)
   - Clarification of known information in proposed setting
   - Identification of information gaps
   - Alternative sources of information and the appropriateness thereof
Session 5: Case Scenarios & Questions to Inform Development of a Risk Assessment Framework

• How to justify the use of excipients (novel, established) in paediatrics? What are the hurdles faced?
• Risk assessment of excipients in paediatrics
  – Can a common template or approach (framework) be developed for implementing risk assessments for individual excipients?
  – What minimum information is required? What additional data is required?
  – What circumstances and factors should be considered regarding the justification for juvenile tox studies?
  – Should toxicology studies with the final formulation be conducted? If so, when & which studies?
  – What alternative options are available if no additional information is available?
  – What clinical trial design factors can be incorporated to provide information on the safety of excipients?
  – Where are the knowledge gaps and how would you prioritize studies needed to approach the evaluation of excipients for paediatrics?
• Would the proposed framework help address the issues of use of excipients in paediatrics?
  – What are the pros and cons of the presented framework?
  – What additional elements would you consider in the framework?
• Can we evaluate data on excipients and present in a format which will satisfy regulators.
  – Should a standardized template/monograph be created?
• Where to find the existing information?
  – extending the FDA inactive ingredient database to paediatrics
  – Platform to share information? (eg, STEP database)